We’re pursuing every opportunity to develop and bring our investigational drugs to patients
CONGRESS ACTIVITIES
Please join us for the Arena satellite symposium
From theory to practice: Adapting guidance to meet patient-specific needs and goals in UC managementThe symposium will stream live on the ECCO 2022 virtual meeting platform on Friday, February 18, at
Accepted Abstract
A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
Accepted Abstract
A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female Volunteers
UPCOMING CONGRESSES
Digestive Disease Week (DDW) 2022
May 21-24, 2022
San Diego, CA
British Society of Gastroenterology (BSG) 2022 Annual Meeting
June 20-23, 2022
Birmingham, UK
Viszeralmedizin 2022
Sept 12-17, 2022
Hamburg, Germany
United European Gastroenterology (UEG) Week 2022
Oct 8-11, 2022
Vienna & Online
American College of Gastroenterology (ACG) 2022
Oct 21-26, 2022
Charlotte, NC
Advances in Inflammatory Bowel Diseases (AIBD) 2022
December 5-7, 2022
Orlando, FL
ARENA AT PAST CONGRESSES
P0524
Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A
P0518
Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-label Extension
P2628
Real-world Treatment (Tx) Patterns and Healthcare Costs Among US Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)
P0390
Pharmacokinetics, Safety, and Tolerability of Etrasimod (APD334) in Subjects With Mild, Moderate, or Severe Hepatic Impairment: A Single-dose, Open-label,
P0406
Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-label Extension
P0428
Real-world Treatment Patterns and Healthcare Costs Among US Commercially Insured Adults Initiating Biologics for Ulcerative Colitis
OP115
Efficacy and Safety of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of Cannabinoid Receptor 2, for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome: Results From a Phase 2b Randomized Study
